Virginia Patent of the Month – April 2023

Antibiotic resistance is a growing problem worldwide, with at least 2 million people acquiring serious infections with bacteria that are resistant to antibiotics each year in the United States alone. The problem adds considerable and avoidable costs to the healthcare system, with the total economic costs of antibiotic resistance ranging as high as $20 billion in direct healthcare costs and additional costs to society for lost productivity as high as $35 billion annually.

Fortunately, a new invention by I2PURE Corp offers a promising solution. Molecular iodine (I2) has been shown to be highly effective against MRSA, the most common causative pathogen of hospital-treated acute bacterial skin infections. The advantage of I2 is that it offers a broad-spectrum antimicrobial nasal agent with substantial in vitro and in vivo evidence, and its activity is effective against both common bacterial and antibiotic-resistant species, without generating resistant bacterial strains.

I2PURE’s invention offers a pharmaceutically acceptable formulation based upon an emollient organic carrier molecule that can stabilize molecular iodine for at least nine months at room temperature. The formulation delivers free I2 at concentrations that are 10 to 400 times higher than those found in typical iodophors, is emollient, and lowers the effective vapor pressure of I2, allowing it to remain in the composition for an extended period.

This innovation offers a significant improvement over the current solutions, as their iodophors lose free molecular iodine rapidly and do not provide a persistent antimicrobial barrier. The new composition offers a topical solution that can maintain high concentrations of free I2 in contact with mammalian tissue for extended periods of time, making it a promising solution for preventing and treating antibiotic-resistant infections.

I2PURE’s I2 is able to kill pathogens on contact while leaving healthy tissue unharmed. It can be used to destroy pathogens in, on and above skin and on surfaces. The formulation can be readily included in custom blends for specific needs, creating unlimited potential in the battle against microbes.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts